To verify the differences in P53, DNMT3A, FLT3, and NPM1 mutation rates under different FAT1 genetic statuses observed in the LAML-KR cohort, we conducted the same comparative analysis in the Venetoclax-AML cohort. This evidence concerns the gene DNMT3A and acute myeloid leukemia.